Prevalence of Metabolic Syndrome among Breast Cancer Survivors in East Coast of Peninsular Malaysia
Background: To date, limited data are available on metabolic syndrome prevalence among breast cancer survivors in Malaysia. Therefore, this study was conducted to determine the prevalence of metabolic syndrome and abnormal metabolic syndrome components among breast cancer survivors in East Coast of Peninsular Malaysia.
Methods: This cross-sectional study included 95 breast cancer survivors (age 53.7±7.6 years) who have completed main cancer treatments for ≥6 months. Cancer survivors were recruited from two main government hospitals in Kelantan and Terengganu using a purposive sampling method.
Results: According to the Harmonized criteria, the metabolic syndrome prevalence was 50.5%. Among those with metabolic syndrome, the most prevalent abnormal metabolic components were triglycerides (91.2%), fasting blood glucose (79.6%) and HDL-c level (78.4%). Except for total cholesterol and LDL-c, all other metabolic syndrome components were significantly different (p<0.05) between those with and without metabolic syndrome. Significant differences between metabolic syndrome and non-metabolic syndrome groups were found for weight, BMI, waist circumference, body fat percentage and cancer stages (p<0.05). However, no significant relationship was reported between sociodemographic, clinical parameters and metabolic syndrome among breast cancer survivors in this study.
Conclusions: Metabolic syndrome was highly prevalent among breast cancer survivors. It is recommended for health care professionals to closely monitor and improve the triglycerides, blood glucose and HDL-c level of the breast cancer survivors under their care to control the detrimental effect of metabolic syndrome.
Figure 1
Figure 2
This is a list of supplementary files associated with this preprint. Click to download.
Supplementary Material (Table 3 Relationship between characteristics of breast cancer survivors and metabolic syndrome)
Posted 20 Jan, 2021
On 28 Jan, 2021
On 12 Jan, 2021
On 12 Jan, 2021
On 12 Jan, 2021
On 05 Jan, 2021
Received 14 Dec, 2020
On 06 Dec, 2020
Invitations sent on 11 Nov, 2020
On 08 Nov, 2020
On 08 Nov, 2020
On 08 Nov, 2020
On 08 Oct, 2020
Received 01 Oct, 2020
Received 19 Sep, 2020
On 11 Sep, 2020
Invitations sent on 10 Sep, 2020
On 10 Sep, 2020
On 09 Sep, 2020
On 08 Sep, 2020
On 08 Sep, 2020
On 11 Aug, 2020
On 10 Aug, 2020
On 10 Aug, 2020
On 22 Jun, 2020
Received 16 Jun, 2020
Received 07 Jun, 2020
On 19 May, 2020
On 19 May, 2020
Received 10 May, 2020
On 26 Apr, 2020
Invitations sent on 25 Apr, 2020
On 14 Apr, 2020
On 13 Apr, 2020
On 13 Apr, 2020
On 09 Apr, 2020
Prevalence of Metabolic Syndrome among Breast Cancer Survivors in East Coast of Peninsular Malaysia
Posted 20 Jan, 2021
On 28 Jan, 2021
On 12 Jan, 2021
On 12 Jan, 2021
On 12 Jan, 2021
On 05 Jan, 2021
Received 14 Dec, 2020
On 06 Dec, 2020
Invitations sent on 11 Nov, 2020
On 08 Nov, 2020
On 08 Nov, 2020
On 08 Nov, 2020
On 08 Oct, 2020
Received 01 Oct, 2020
Received 19 Sep, 2020
On 11 Sep, 2020
Invitations sent on 10 Sep, 2020
On 10 Sep, 2020
On 09 Sep, 2020
On 08 Sep, 2020
On 08 Sep, 2020
On 11 Aug, 2020
On 10 Aug, 2020
On 10 Aug, 2020
On 22 Jun, 2020
Received 16 Jun, 2020
Received 07 Jun, 2020
On 19 May, 2020
On 19 May, 2020
Received 10 May, 2020
On 26 Apr, 2020
Invitations sent on 25 Apr, 2020
On 14 Apr, 2020
On 13 Apr, 2020
On 13 Apr, 2020
On 09 Apr, 2020
Background: To date, limited data are available on metabolic syndrome prevalence among breast cancer survivors in Malaysia. Therefore, this study was conducted to determine the prevalence of metabolic syndrome and abnormal metabolic syndrome components among breast cancer survivors in East Coast of Peninsular Malaysia.
Methods: This cross-sectional study included 95 breast cancer survivors (age 53.7±7.6 years) who have completed main cancer treatments for ≥6 months. Cancer survivors were recruited from two main government hospitals in Kelantan and Terengganu using a purposive sampling method.
Results: According to the Harmonized criteria, the metabolic syndrome prevalence was 50.5%. Among those with metabolic syndrome, the most prevalent abnormal metabolic components were triglycerides (91.2%), fasting blood glucose (79.6%) and HDL-c level (78.4%). Except for total cholesterol and LDL-c, all other metabolic syndrome components were significantly different (p<0.05) between those with and without metabolic syndrome. Significant differences between metabolic syndrome and non-metabolic syndrome groups were found for weight, BMI, waist circumference, body fat percentage and cancer stages (p<0.05). However, no significant relationship was reported between sociodemographic, clinical parameters and metabolic syndrome among breast cancer survivors in this study.
Conclusions: Metabolic syndrome was highly prevalent among breast cancer survivors. It is recommended for health care professionals to closely monitor and improve the triglycerides, blood glucose and HDL-c level of the breast cancer survivors under their care to control the detrimental effect of metabolic syndrome.
Figure 1
Figure 2